Ovid Therapeutics (OVID) Invested Capital (2019 - 2020)
Ovid Therapeutics (OVID) posted Invested Capital of $2.4 million for Q4 2020, up 946.63% on a QoQ basis from $226536.0 in Q3 2020, and up 21845.5% year-over-year from N/an in Q1 2020.
Ovid Therapeutics (OVID) Invested Capital (2019 - 2020) Analysis & Trends
Ovid Therapeutics' Invested Capital history runs 2 years deep, the most recent figure standing at $2.4 million for Q4 2020.
- Quarterly Invested Capital rose 21845.5% year-over-year to $2.4 million in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $2.4 million (up 815.62% YoY) and the FY2020 annual result came in at $2.4 million, up 21845.5% from the prior year.
- Invested Capital was $2.4 million for Q4 2020 at Ovid Therapeutics, up from $226536.0 in the prior quarter.
- Across five years, Invested Capital topped out at $2.4 million in Q4 2020 and bottomed at $10804.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | 116.14 Mn |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | - |
| 10 | Ovid Therapeutics | 120.91 Mn | -34.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 226,536.00 |
| Jun 30, 2020 | 10,804.00 |
| Mar 31, 2020 | 10,804.00 |
| Dec 31, 2019 | 10,804.00 |
| Sep 30, 2019 | 337,773.00 |
| Jun 30, 2019 | 1.06 Mn |